bluebird bio (NASDAQ:BLUE) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. The company reported quarterly sales of $10.60 million which missed the analyst consensus estimate of $18.05 million by 41.27 percent. This is a 14.46 percent decrease over sales of $12.39 million the same period last year.